A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(TM) Administered Concomitantly Versus Non-Concomitantly With PNEUMOVAX(TM) 23 in Subjects 60 Years of Age and Older.

Trial Profile

A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(TM) Administered Concomitantly Versus Non-Concomitantly With PNEUMOVAX(TM) 23 in Subjects 60 Years of Age and Older.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Pneumococcal vaccine (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 May 2010 Primary endpoint identified as geometric mean antibody titre as reported by ClinicalTrials.gov.
    • 15 May 2009 Actual end date 1 Apr 2008 added as reported by ClinicalTrials.gov record.
    • 27 Dec 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top